Talk:Vedolizumab

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Vedolizumab.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Cost

Vedolizumab (Entyvio) is one of those very expensive drugs that insurers often refuse to authorize. It was discussed in a story in ProPublica:

https://www.propublica.org/article/unitedhealth-healthcare-insurance-denial-ulcerative-colitis

UnitedHealthcare Tried to Deny Coverage to a Chronically Ill Patient. He Fought Back, Exposing the Insurer’s Inner Workings.

by David Armstrong, Patrick Rucker and Maya Miller

ProPublica

2 February 2023

It's hard to get a meaningful price for an expensive drug, but one reported figure in a WP:MEDRS was $406,629:

https://www.gastroenterologyandhepatology.net/archives/october-2016/the-cost-effectiveness-of-vedolizumab-for-inflammatory-bowel-disease-a-review-of-the-current-literature/

The Cost-Effectiveness of Vedolizumab for Inflammatory Bowel Disease: A Review of the Current Literature

Gastroenterology & Hepatology

October 2016 12(10):617-621

Yecheskel Schneider, Monica Saumoy, Shirley Cohen-Mekelburg, Adam F. Steinlauf, and Ellen J. Scherl

--Nbauman (talk) 14:13, 28 June 2023 (UTC)[reply]

@Nbauman - Your comment implies that the drug costs much more than it does. It is pricey, alright, but per the Gastroenterology and Hepatology article you reference, the cost of vedolizumab was $301,969/MH. "MH" is defined as "The goals of biologic therapy are mucosal healing (MH) and reversal of the natural history of progressive structural damage due to chronic inflammation." That could happen over months or years.

Thank you, Wordreader (talk) 06:02, 27 December 2023 (UTC)[reply]